Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19804204 | 0.93 | CYP4A11 (0.38) | CYP4F2CYP4A11MEN1KMT2ARARB | |
| SCHEMBL19804224 | 0.90 | PTGER4 (0.40) | CYP4F2CYP4A11MEN1KMT2AHSD17B1 | |
| SCHEMBL19804322 | 0.89 | THRB (0.39) | CYP4F2CYP4A11RARBPPARACA2 | |
| SCHEMBL19796460 | 0.85 | CYP4F2 (0.38) | CYP4F2CYP4A11RARBHSD17B1MCL1 | |
| SCHEMBL19804668 | 0.84 | FFAR1 (0.42) | FFAR1PTGER4 | |
| SCHEMBL19804382 | 0.84 | POLB (0.44) | MEN1KMT2AFFAR1PPARAPTGER4 | |
| SCHEMBL19796225 | 0.83 | MCL1 (0.40) | CYP4F2CYP4A11RARBHSD17B1MCL1 | |
| SCHEMBL19624374 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11RARBFFAR1PPARA | |
| SCHEMBL19804538 | 0.82 | S1PR1 (0.37) | FFAR1PPARAHCAR2 | |
| SCHEMBL19624572 | 0.82 | MEN1 (0.37) | CYP4F2CYP4A11MEN1KMT2AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CYP4F2 2577/4885CYP4A11 1991/4885MEN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.